Matrin3 is an RNA-binding protein that is localized in the nuclear matrix. Although various roles in RNA metabolism have been reported for Matrin3, in vivo target RNAs to which Matrin3 binds directly have not been investigated comprehensively so far. Here, we show that Matrin3 binds predominantly to intronic regions of pre-mRNAs. Photoactivatable Ribonucleoside-Enhanced Cross-linking and Immunoprecipitation (PAR-CLIP) analysis using human neuronal cells showed that Matrin3 recognized pyrimidine-rich sequences as binding motifs, including the polypyrimidine tract, a splicing regulatory element. Splicing-sensitive microarray analysis showed that depletion of Matrin3 preferentially increased the inclusion of cassette exons that were adjacent to introns that contained Matrin3-binding sites. We further found that although most of the genes targeted by polypyrimidine tract binding protein 1 (PTBP1) were also bound by Matrin3, Matrin3 could control alternative splicing in a PTBP1-independent manner, at least in part. These findings suggest that Matrin3 is a splicing regulator that targets intronic pyrimidine-rich sequences.
Introduction
RNA-binding proteins (RBPs) regulate various aspects of RNA processing, such as splicing, editing, modification, transport and stability. Recently, it has been estimated that more than 1100 RBPs are expressed in human tissues (Castello et al. 2013) . These RBPs act on each target RNA cooperatively or competitively to ensure the precise regulation of each processing step. Indeed, mutations that lead to genetic diseases have been identified in approximately 10% of the genes that encode RBPs (Castello et al. 2013) . Consequently, it is important to elucidate the functions of each RBP by, for instance, identifying the target RNAs and the binding sites of each RBP comprehensively. However, the number of RBPs whose functions or targets have been identified is very limited.
One of the most powerful methods to identify the targets of RBPs with high resolution is cross-linking and immunoprecipitation (CLIP), together with related methods, such as Photoactivatable Ribonucleoside-Enhanced CLIP (PAR-CLIP) (Hafner et al. 2010) . In PAR-CLIP, 4-thiouridine (4-SU) is added to the cell culture medium and is incorporated into RNAs in place of uridine. This results in strong cross-linking between the 4-SU in the RNA and bound RBPs. In addition, cross-linked 4-SU is converted into cytosine (C) rather than thymidine (T) during reverse transcription, which thereby marks the binding site of the protein at a single-nucleotide resolution (Hafner et al. 2010; Lebedeva et al. 2011; Yokoshi et al. 2014; Li et al. 2015) . Recently, we have successfully elucidated the function of Ataxin-2, which promotes mRNA stability by direct binding to target mRNAs, through the comprehensive identification of its targets using PAR-CLIP (Yokoshi et al. 2014) .
Matrin3 is a highly conserved nuclear matrix protein that can bind to both DNA and RNA through zinc finger domains (ZF1 and ZF2) and RNA recognition motifs (RRM1 and RRM2), respectively ( Fig. 1A) (Hibino et al. 2006) . It has been reported that Matrin3 participates in various aspects of RNA metabolism, including transcription, mRNA stabilization, gene silencing and the retention of hyperedited RNA, by binding to other RBPs, such as DHX9, hnRNPK, Argonaute, p54nrb and PSF (protein-associated splicing factor) (Zhang & Carmichael 2001; H€ ock et al. 2007; Salton et al. 2011) . In addition, it was reported recently that Matrin3 regulates alternative splicing in a polypyrimidine tract binding protein 1 (PTBP1)-dependent and PTBP1-independent manner in HeLa cells (Joshi et al. 2011; Coelho et al. 2015) . However, the target RNAs and binding motifs of Matrin3 have not been investigated comprehensively by the CLIP method so far. Of note, mutations that cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, have been identified in many genes that encode RBPs, including TDP-43, FUS (fused in sarcoma) and hnRNPA1 (Iguchi et al. 2013) . Causative mutations for ALS have been also identified in the MATR3 gene, which encodes Matrin3 (Johnson et al. 2014) , although the disease mechanism driven by Matrin3 remains to be determined. Consequently, in terms of elucidating the disease mechanism, it is pivotal to identify the target RNAs and functions of Matrin3, especially in neuronal cells.
In this study, we carried out PAR-CLIP for Matrin3 using human neuroblastoma-derived SH-SY5Y cells. We showed that Matrin3 bound predominantly to intronic regions of pre-mRNAs with pyrimidine-rich sequences. An in vitro binding assay confirmed that Matrin3 could bind directly to RNAs with pyrimidine-rich sequences. Furthermore, combinatorial analysis of data obtained using a splicing-sensitive microarray with the PAR-CLIP data showed that Matrin3 knockdown preferentially increased the inclusion of exons that contained Matrin3-binding sites in adjacent introns. We found that this splicing control did not affect gene expression greatly and was, at least in part, independent of PTBP1.
Results

Matrin3 binds predominantly to intronic regions in pre-mRNAs
To identify the target RNAs to which Matrin3 binds directly in vivo, we carried out PAR-CLIP analysis of endogenous Matrin3 using SH-SY5Y cells. After 4-SU had been added to the cell culture medium, the cells were cultured for 14-16 h and then irradiated with UV to cross-link the bound proteins with 4-SU-incorporated RNAs. Matrin3-RNA complexes were immunoprecipitated from cell lysate that had been prepared after the cross-linking and then the RNAs that were bound to Matrin3 were fragmented by treatment with micrococcal nuclease (MNase) and radiolabeled. After the samples had been separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), the autoradiographic analysis showed that certain RNAs were bound directly to Matrin3 (Fig. 1B) . The RNA fragments were purified from the gel and reverse-transcribed to generate a cDNA library, which was subjected to deep sequencing. We carried out the PAR-CLIP analysis in duplicate and obtained 193 798 031 and 278 640 634 sequence reads for Replicate 1 and Replicate 2, respectively (Table S1 in Supporting Information). After the low-quality and short reads (<20 nt) had been removed, the remaining sequence reads were aligned with the human reference genome (hg19) with allowance of up to two mismatches. Given that 4-SU cross-linked with protein is converted into C during the reverse transcription (RT) step, thereby indicating the binding site of proteins at a single-nucleotide resolution, we calculated the proportion of T-to-C mismatches among all the possible mismatches. We found that~80% of them were Tto-C in Replicate 1 (Fig. 1C) , and similar results were also obtained for Replicate 2. This confirmed that the majority of the sequence reads was derived from RNAs bound directly to Matrin3. Finally, we identified 1 882 819 and 1 767 968 clusters of Matrin3-binding sites in 21 419 and 20 677 genes for Replicate 1 and Replicate 2, respectively, using PARalyzer (Corcoran et al. 2011) (Table S1 in Supporting Information). More than 92% of the target genes overlapped between Replicate 1 and Replicate 2 ( Fig. S1 in Supporting Information), and therefore, we used the data from Replicate 1 for the subsequent analysis. Although 15% and 12% of the clusters were mapped to intergenic and repeat regions, respectively, the majority (72%) of the clusters were annotated to regions that encompassed protein-coding genes (mRNA). Furthermore, most of these clusters (90%) were located within intronic regions (Fig. 1D) . These results suggest that nuclear Matrin3 binds predominantly to intronic regions in pre-mRNAs.
Gene Ontology (GO) analysis of the 13 012 protein-coding genes that contained Matrin3-binding sites showed that Matrin3 targeted various types of gene broadly and there was no preference for the specific categories (Table S2 in Supporting Information). However, many of the highest-ranked genes with abundant binding sites were involved in Genes to Cells (2017) 22, 785-798 neuronal functions, including limbic system-associated membrane protein (LSAMP), autism susceptibility candidate 2 (AUTS2), neuron navigator 2 (NAV2) and calcium voltage-gated channel auxiliary subunit alpha 2delta1 (CACNA2D1) ( Table S3 in Supporting  Information) . Furthermore, we examined 16 ALSrelated genes (Taylor et al. 2016) and found that 14 genes contained Matrin3-binding sites, including Fused in sarcoma (FUS), hnRNPA1 and TAR DNAbinding protein (TARDBP), which encodes TDP-43 (Table S4 in Supporting Information). Among these genes, MATR3 contained the greatest number of Matrin3-binding sites, which suggests that Matrin3 expression might be autoregulated.
Pyrimidine-rich sequences are the preferred motifs targeted by Matrin3
Next, we examined the motif sequences that were recognized by Matrin3 using cERMIT, which analyzes the sites that show a T-to-C conversion to identify binding motifs (Georgiev et al. 2010 ). An analysis of 7-mer motifs showed that long pyrimidine-rich sequences were the top candidates for Matrin3 targets ( Fig. 2A and Table S5 in Supporting Information). The polypyrimidine tract is a wellcharacterized motif that is composed of 10-20 nucleotides that are rich in pyrimidines and is located approximately 3-40 bp upstream of a 3 0 splicing site (3 0 ss) to control splicing (Reed 1996) . Consequently, we analyzed the position of the Matrin3-cross-linked sites that contained T-to-C conversions around 3 0 ss. This analysis showed that Matrin3-binding sites were relatively highly enriched in the regions 5-15 bp upstream of 3 0 ss, which correspond to polypyrimidine tracts (Fig. 2B) .
To confirm that Matrin3 binds directly to RNAs that contain pyrimidine-rich sequences, we planned to perform electrophoresis mobility shift assays (EMSAs) (Kawahara & Mieda-Sato 2012; Yokoshi et al. 2014) . However, we failed to prepare recombinant Matrin3 by either expression in Escherichia coli or using a baculovirus expression system. Consequently, we carried out reverse EMSAs by radiolabeling proteins instead of RNAs (Filion et al. 2006) . In this reverse assay, nondenatured proteins can migrate into the gel only when they are bound to nucleic acids, which have a negative charge. First, we validated this assay system using TDP-43, an RNA-binding protein, which was shown previously to bind to a UGrich sequence, leading to a band shift in an EMSA, but did not bind to miR-143-3p (Kawahara & Mieda-Sato 2012) . As expected, radiolabeled TDP-43 showed no migration in the absence of RNA (Fig. S2A in Supporting Information). However, TDP-43 migrated efficiently into the gel when it was mixed with 12-UG-repeat RNA, but not with miR-143-3p. These data validated the application of reverse EMSA for RNA and RBPs. Then, we applied this reverse EMSA to Matrin3. After confirming the expression of radiolabeled wild-type (WT) Matrin3 by autoradiography (Fig. 2C) , we carried out a reverse EMSA with RNA that contained pyrimidine-rich sequences derived from a certain region in Intron 1 (chr13; 102 901 094-102 901 248) of fibroblast growth factor 14 (FGF14), which was one Genes to Cells (2017) 22, 785-798 of the highest-ranking target sites of Matrin3 (Table S3 in Supporting Information). We termed this sequence FGF14a (Fig. S2B in Supporting Information). We observed that Matrin3 migrated in the reverse EMSA in a manner that depended on the dose of FGF14a RNA (Fig. 2D ). In contrast, this migration was abolished when cold Matrin3 was added as a competitor before the addition of radiolabeled Matrin3 (Fig. S2C in Supporting Information), which suggests significant binding of Matrin3 to FGF14a. The binding efficiency was reduced when the length of the pyrimidine-rich sequence was shortened (FGF14b) (Fig. 2E) . Furthermore, we could not observe substantial binding of Matrin3 to RNA in the absence of the pyrimidine-rich sequence (FGF14c). Next, we prepared radiolabeled Matrin3 without RNA recognition motifs (DRRM1 + 2), and this failed to bind to any FGF14 RNA fragments ( Fig. 2C ,E). Collectively, these results suggest that Matrin3 can bind directly to RNA that contains pyrimidine-rich sequences.
Matrin3 controls alternative splicing without affecting gene expression
Given that Matrin3 targets intronic pyrimidine-rich sequences in pre-mRNAs, we knocked down Matrin3 using small interfering RNA (siRNA) and analyzed how depletion of Matrin3 affected the gene expression and the splicing pattern using a microarray (Fig. 3A) . Although knockdown of Matrin3 significantly affected the expression level of 1339 genes, which did not include Matrin3 mRNA per se, most of the changes were subtle or moderate. The expression of only 78 genes was either up-regulated or down-regulated more than twofold. Integration of the PAR-CLIP data showed that only 14 of these 78 genes contained Matrin3-binding sites. Furthermore, we could observe no significant differences in the cumulative distributions of the expression changes between the genes with Matrin3-binding sites and those without binding sites (Fig. S3 in Supporting Information) . From these results, we concluded that binding of Matrin3 largely does not affect the expression of individual mRNAs.
Next, to examine the extent to which Matrin3 affects alternative splicing, we counted the number of cassette exons whose signal intensity was changed significantly after depletion of Matrin3 by setting the filter criteria as |splicing index value| ≥ 2 (Yao et al. 2016) . In addition, given that signal intensity was also affected by the alteration of gene expression, we limited the subject to the genes whose expression level was decreased or increased less than twofold after Matrin3 knockdown. This analysis showed that depletion of Matrin3 affected both exon inclusion and skipping to a similar extent. Namely, 577 and 521 cassette exons were included and excluded significantly, respectively, after Matrin3 knockdown ( Fig. S4 in Supporting Information). However, when we limited the subject to exons that were adjacent to introns that contained Matrin3-binding sites, exon inclusion predominated (~70%) (Fig. 3B ). Matrin3-binding sites were enriched at both ends of the introns adjacent to these included exons, as compared with the excluded exons, and the density of the binding sites was highest in the region that corresponded to the polypyrimidine tract (Fig. 3C ). Taken together, the data suggested that Matrin3 controls alternative splicing and an enrichment of Matrin3-binding sites in adjacent introns predominantly promotes exon skipping.
Target sites of Matrin3 are largely also recognized by PTBP1
PTBP1 is one of the RBPs that bind to polypyrimidine tract and regulate splicing (Valcarcel et al. 1996; Wagner & Garcia-Blanco 2001; Xue et al. 2009; Llorian et al. 2010) . To evaluate the degree to which the target binding sites and genes of Matrin3 overlap with those of PTBP1, we carried out PAR-CLIP analysis of endogenous PTBP1 in SH-SY5Y cells in duplicate (Fig. 4A ). This yielded 80 471 and 77 832 clusters of PTBP1-binding sites from 202 953 476 and 247 390 487 sequence reads for Replicate 1 and Replicate 2, respectively (Table S1 in Supporting Information), which was only~40% of the number of clusters obtained for Matrin3. This difference might be due to differences in the amount of RNA fragments extracted from the gels to create the cDNA libraries or simply due to the different scale of gene regulation by the two proteins. Given that the targeted genes overlapped greatly between Replicate 1 and Replicate 2 (Fig. S5 in Supporting Information), we used the data from Replicate 1 for the subsequent analysis. The motif analysis showed that pyrimidinerich motifs were the top target sequences recognized by PTBP1 as expected, and the motifs were very similar to those targeted by Matrin3 (Fig. 4B and Table S6 in Supporting Information). In addition, 96% of the PTBP1 target genes (Fig. 4C) and 77% of the PTBP1-binding sites (Fig. 4D) were also targeted by Matrin3. These results suggest that Matrin3 and PTBP1 largely share binding sites and favor pyrimidine-rich sequences.
Matrin3-mediated regulation of alternative splicing is partly independent of PTBP1
Given that a certain amount of the Matrin3 proteins binds to PTBP1 (Joshi et al. 2011; Coelho et al. 2015) , we examined whether Matrin3-dependent control of alternative splicing required PTBP1. For this purpose, we knocked down PTBP1 in SH-SY5Y cells using siRNA. However, this resulted in compensatory up-regulation of PTBP2, a neuronal homologue of PTBP1, as reported previously (Boutz et al. 2007) , which is usually expressed at low levels in SH-SY5Y cells (Fig. 5A) . Consequently, we knocked down both PTBP1 and PTBP2 and compared the pattern of splicing with that in Matrin3-depleted cells in which we had confirmed that the amount of PTBP1 was not affected (Fig. 3A) . We selected three cassette exons that contained Matrin3-binding sites but no PTBP1-binding sites in the adjacent intron(s), namely Exon 14 (chr3; 9 478 534-9 478 572) of SET domain containing 5 (SETD5), Exon 20 (chr14; of tubulin tyrosine ligase-like 5 (TTLL5) and Exon 5a (chr12; 56 308 060-56 308 150) of Within BGCN (WIBG). Semiquantitative RT-PCR analysis showed that the inclusion of these exons was up-regulated significantly only when Matrin3 was knocked down (Fig. 5B-D) . In contrast, the inclusion of Exon 7 (chr7; 44 695 917-44 695 961) of oxoglutarate dehydrogenase (OGDH), which contains binding sites for both Matrin3 and PTBP1 in the adjacent introns, was promoted significantly after the knockdown of either Matrin3 or PTBPs (Fig. 5E ). We could not observe any significant alteration in the splicing pattern for Exon 32 (chr7; 73 480 274-73 480 327) of elastin (ELN) after the depletion of either Matrin3 or PTBPs (Fig. 5F ). This gene contains no binding sites for either Matrin3 or PTBP1 in the adjacent introns. Collectively, the data suggest that Matrin3 controls alternative splicing likely through direct binding to adjacent introns in a manner that is independent of PTBP1, at least in part.
Discussion
Although it has been reported that Matrin3 can bind directly to RNA in vitro (Hibino et al. 2006; Yamazaki et al. 2014) and iCLIP data for Matrin3 were used to study alternative splicing (Coelho et al. 2015) , the in vivo targets of Matrin3 remain to be investigated comprehensively. In the present study, we carried out PAR-CLIP analysis for Matrin3 for the first time and successfully identified transcriptome-wide target RNAs and binding motifs of endogenous Matrin3. This analysis showed that the majority of the binding sites of Matrin3 are located in intronic regions of pre-mRNAs. Furthermore, we found that Matrin3 preferentially recognized pyrimidine-rich sequences as binding motifs, which we confirmed by an in vitro binding assay. This result might not be surprising, given that much of the core sequences in the RRMs of Matrin3 and PTBP1 are identical (Matsushima et al. 1996) . Indeed, previous CLIP and PAR-CLIP analyses for HeLa cells (Xue et al. 2009; Ling et al. 2016 ) and our PAR-CLIP analysis for SH-SY5Y cells identified pyrimidine-rich sequences as the binding motifs of PTBP1 and we found that 77% of PTBP1-binding clusters were shared by Matrin3.
We showed that Matrin3 controlled alternative splicing in a manner that was independent of PTBPs, at least in part, and acted predominantly as a repressor, as shown previously (Coelho et al. 2015) . However, although Coelho et al. (2015) observed uniformly elevated binding of Matrin3 throughout introns adjacent to repressed exons, with no discrete peaks or enriched motifs, we found a discrete peak near the 3 0 ss, which corresponds to the location of the polypyrimidine tract. This discrepancy might be attributed to the differences in methodology or the quality of the CLIP libraries. The mechanism that underlies Matrin3-mediated splicing regulation remains unknown. However, it has been reported that PTBP1 and hnRNP C bind to pyrimidine-rich sequences and regulate alternative splicing by competing with U2AF65, which also binds to pyrimidine-rich sequences and promotes exon inclusion (Singh et al. 1995; Sauliere et al. 2006; Zarnack et al. 2013 ). Indeed, U2AF65 shows a binding peak near the 3 0 ss of cassette exons (Zarnack et al. 2013; Coelho et al. 2015) , which is similar to the peak that we observed for Matrin3. Therefore, although further study is needed to elucidate how Matrin3, PTBP1 and hnRNP C cooperatively or competitively share the same binding sites to regulate splicing, it is possible that Matrin3 also controls alternative splicing by competing with U2AF65.
It has been reported that point mutations in the MATR3 gene cause ALS and distal myopathy (Senderek et al. 2009; Johnson et al. 2014) . These point mutations have no effect on the localization of Matrin3 in Chinese hamster ovary (CHO) cells (Gallego-Iradi et al. 2015) . However, Matrin3 is found to be redistributed in the cytoplasm in some neurons of the spinal cord in transgenic mice over-expressing wild-type Matrin3, which exhibit muscle atrophy and weakness (Moloney et al. 2016) . Therefore, although it still remains unknown whether either loss of function or gain of function is the main cause of these diseases, identification of the target RNAs and the function of Matrin3 could be the first step to elucidate the disease mechanism. Indeed, using neuronal cells for PAR-CLIP analysis, we identified various genes that are involved in neuronal functions and those that are mutated in familial ALS as targets of Matrin3. We further found that Matrin3 participates in the control of splicing of these genes. It is known that the nervous system shows high levels of alternative splicing (Grosso et al. 2008) and aberrant splicing was observed in the patients with ALS (Ling et al. 
Experimental procedures
Cell culture SH-SY5Y cells were maintained in Dulbecco's modified Eagle's medium: nutrient mixture F-12 (DMEM/F-12; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 15% fetal bovine serum (FBS; Thermo Fisher Scientific) as described previously (Kawahara & Mieda-Sato 2012) . Cells were maintained at 37°C in the presence of 5% CO 2 .
Antibodies
The primary antibodies used for PAR-CLIP and Western blotting were as follows: goat polyclonal anti-Matrin3 antibody (sc-55723; Santa Cruz, Dallas, TX, USA), goat polyclonal anti-hnRNP I (PTBP1) antibody (sc-16547; Santa Cruz), mouse polyclonal anti-PTBP2 antibody (H00058155-A01; Abnova, Taipei City, Taiwan) and mouse monoclonal anti-GAPDH antibody (M171-3; MBL, Nagoya, Japan). Normal goat IgG (sc-2028; Santa Cruz) was used as a control in the PAR-CLIP.
Western blot analysis
Total cell lysates were separated using SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA) and immunoblotted with primary antibodies using the SNAP i.d. 
PAR-CLIP analysis
PAR-CLIP analysis was carried out as described previously (Hafner et al. 2010; Lebedeva et al. 2011; Yokoshi et al. 2014; Li et al. 2015) with some modifications. Briefly, SH-SY5Y cells were cultured on 60 15-cm culture dishes in the presence of 100 lM 4-SU (Sigma, St Louis, MO, USA) for 14-16 h. After the medium had been aspirated, the cells were crosslinked on ice by irradiation with 365 nm UV at 150 mJ/cm 2 in a UV cross-linker (FS-1500L; Funakoshi). The cells were collected and resuspended in two volumes of NP-40 lysis buffer (50 mM HEPES pH 7.5, 150 mM KCl, 2 mM EDTA, 0.5% NP-40, 0.5 mM DTT) with 19 complete, EDTA-free protease inhibitor cocktail (PI; Roche, Indianapolis, IN, USA). After incubation with rotation for 30 min at 4°C, the cell homogenates were homogenized 15 times with a tight pestle in an ice-cold Dounce tissue grinder (Wheaton, Millville, NJ, USA). Then, whole-cell lysate was collected by centrifugation at 20 000 g for 30 min at 4°C and treated with 5 U/mL RNase T1 (Thermo Fisher Scientific) for 15 min at 22°C. After the antibody for either Matrin3 or PTBP1 or normal goat IgG had been conjugated to magnetic Protein G Dynabeads (Thermo Fisher Scientific), 10 mL of the whole-cell lysate was incubated with the beads (25 lL of beads and 6 lg of antibody per mL of cell lysate) at 4°C for 1 h with rotation. Then, after the beads had been resuspended with micrococcal nuclease (MNase) buffer (50 mM Tris-HCl pH 7.4, 5 mM CaCl 2 ), 0.2 gel U/lL MNase (NEB, Ipswich, MA, USA) was added and the mixture was incubated at 37°C for 5 min. The beads were treated with 0.5 U/lL calf intestinal alkaline phosphatase (CIP) in dephospho buffer (50 mM TrisHCl pH 7.9, 0.1 M NaCl, 10 mM MgCl 2 , 1 mM DTT) with 19 PI at 37°C for 10 min with gentle shaking. Then, a 3 0 -linker (L3; 5 0 -p-gugucagucacuuccagcgg-puromycin-3 0 ) that had been synthesized by Dharmacon (Lafayette, CO, USA) was ligated to the RNA fragments in ligase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 0.2 mg/mL BSA, 10 mM ATP) with 0.5 U/lL T4 RNA ligase (Thermo Fisher Scientific) through overnight incubation at 16°C in a Thermomixer comfort (Eppendorf, Hamburg, Germany). To radiolabel the RNA fragments, the beads were incubated with [c-32 P]-ATP (0.5 lCi/lL) and 1 U/lL T4 polynucleotide kinase (NEB) in PNK buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl 2 , 5 mM DTT) with 19 PI at 37°C for 30 min. After three washes with wash buffer (50 mM Tris-HCl pH 7.4, 0.3 M NaCl, 0.05% NP-40, 1 mM DTT), the beads were resuspended in 50 lL of 19 NuPAGE LDS sample buffer (Thermo Fisher Scientific) and boiled at 95°C for 10 min to elute protein-RNA complexes. The eluted samples were loaded onto NuPAGE Novex 4%-12% Bis-Tris gels (Thermo Fisher Scientific) and separated by size. Gels were exposed for 1 h and the radiolabeled RNA fragments were visualized on a phosphorimager (GE Healthcare, Chicago, IL, USA). After the bands that corresponded to the target proteins had been excised, the protein-RNA complexes were electroeluted using a D-tube Dialyzer (Merck Millipore). Then, the samples were treated with 29 proteinase K buffer (100 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM MgCl 2 ) that contained 2 mg/mL proteinase K (Thermo Fisher Scientific) at 55°C for 30 min and the RNA fragments were recovered by phenol extraction and 2-propanol precipitation with glycogen. The purified RNAs were ligated with 2 lM 5 0 -linker (L5; 5 0 -OH-agggaggacgaugcgg-OH-3 0 ), which had been synthesized by Hokkaido System Science (Sapporo, Japan), in ligase buffer with 0.5 U/lL T4 RNA ligase and 19 PI at 16°C overnight. The 5 0 -linker-ligated RNAs were loaded onto 10% TBE-Urea gels (Thermo Fisher Scientific) and separated by size. The gels were exposed for 1 h and the radiolabeled RNAs were visualized on a phosphorimager. Fragments of RNA between 60 and 100 nt in length were excised and the RNAs were eluted by incubation at 65°C for 2 h in RNasefree water and recovered by phenol extraction and 2-propanol precipitation with glycogen. After treatment with 0.1 U/lL DNase I (Thermo Fisher Scientific) at 37°C for 20 min, the denatured RNAs were reverse-transcribed into cDNAs using 0.5 lM P3 primer (5 0 -ccgctggaagtgactgacac-3 0 ) and SuperScript III (Thermo Fisher Scientific) in accordance with the manufacturer's instructions. The resultant cDNAs were amplified by PCR using AccuPrime Pfx SuperMix (Thermo Fisher Scientific) and the primers DSFP5 (5 0 -aatgatacggcgaccaccgactatggat acttagtcagggaggacgatgcgg-3 0 ) and DSFP3 (5 0 -caagcagaagacggcat acgaccgctggaagtgactgacac-3 0 ). The PCR products were loaded onto 10% TBE gels (Thermo Fisher Scientific) and stained with SYBR Safe DNA Gel Stain Dye (Thermo Fisher Scientific). After fragments between 125 and 150 bp in length had been excised and incubated in diffusion buffer (0.5 M ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA, 0.1% SDS) at 50°C for 30 min, the PCR products were purified using a QIAEX II Gel Extraction Kit (QIAGEN, Hilden, Germany). They were then subjected to deep sequencing using a HiSeq 2000 Sequencing System (Illumina, San Diego, CA, USA) with the primer SSP1 (5 0 -ctatggatacttagtcagggaggacgatgcgg-3 0 ) at BGI (Beijing, China) and Macrogen (Kyoto, Japan).
Mapping of the reads
The reads that were obtained by deep sequencing were edited by removing reads that contained ambiguous bases as described previously (Yokoshi et al. 2014) . After the 3 0 adaptor sequence had been stripped away by an in-house Perl script, reads that were less than 20 nt in length were removed. The remaining reads were collapsed using fastx_collapser in FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and then mapped to the reference genome (hg19) using the Bowtie algorithm with allowance of up to two mismatches. For each read, only the best mismatch stratum was reported for up to ten different locations (Yokoshi et al. 2014) . The binding sites were identified using PARalyzer (Corcoran et al. 2011) . We defined a cluster as a site that was represented by at least five reads with T-to-C conversions at two or more locations.
Annotation of the clusters
Annotation data for lincRNA, misc_RNA, Mt_rRNA, Mt_tRNA, rRNA, tRNA, snoRNA, snRNA, repetitive elements, piwi-interacting RNA, microRNA and proteincoding transcripts were downloaded from multiple sources described previously (Ascano et al. 2012; Yokoshi et al. 2014) . Then, the clusters that had been assigned to the category of protein-coding transcript were divided further into coding sequences (CDS), 5 0 untranslated region (UTR), 3 0 UTR and intron. The clusters that had been assigned to multiple categories were assigned a single annotation as described previously (Ascano et al. 2012; Yokoshi et al. 2014) . We identified the genes that harbored the clusters by matching the sequences of each cluster with the gene database GRCh37. p13, which was downloaded from Ensembl using the BioMart tool.
Identification of motifs
To identify motifs in the clusters generated by PARalyzer, the cERMIT tool (Georgiev et al. 2010 ) was downloaded and used as described previously (Ascano et al. 2012; Yokoshi et al. 2014) .
Gene ontology analysis
Matrin3 target genes were subjected to GO analysis using PantherDB (Thomas et al. 2006) .
siRNA knockdown
The siRNA duplexes for Matrin3 (5 0 -gggaugauugggaagaaaaTT-3 0 ) were synthesized by GeneDesign (Osaka, Japan). Predesigned siRNAs for PTBP1 and PTBP2 were obtained from Dharmacon (ON-TARGETplus siRNA). Negative control siRNA (AccuTarget Negative Control siRNA) was obtained from Bioneer (Daejeon, Korea). Transfection of siRNAs was carried out using a Neon â Transfection System 100 lL Kit (Thermo Fisher Scientific). After trypsinization, 5 9 10 6 SH-SY5Y cells were washed twice in Dulbecco's phosphate-buffered saline (DPBS) and resuspended in 100 lL of Buffer R that contained 0.2 lM siRNA. For the double transfection of PTBP1 and PTBP2 siRNAs, 100 lL of Buffer R that contained 0.2 lM siRNA for each PTBP was used. Then, electroporation was carried out with the following parameters: pulse voltage, 1100 V; pulse width, 50 ms; and pulse number, 1. Twenty-four hours after transfection, the cell culture medium was replaced with fresh DMEM/F-12 medium, and the cells were incubated for an additional 24 h and then harvested to extract either total RNA or cell lysate.
Preparation of cell lysates
To prepare cell lysates, the collected cells were washed twice in DPBS. After centrifugation at 5000 g for 5 min at 4°C, five volumes of lysis buffer 1 (20 mM Tris-HCl pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM DTT) with 19 PI were added to the pellet. After transfer to a 1.5-mL tube, the sample was Genes to Cells (2017) 22, 785-798 repeatedly frozen in liquid nitrogen and thawed on ice five times. After centrifugation at 15 000 g for 20 min at 4°C, the supernatant was transferred to a new 1.5-mL tube and stored at À80°C until use.
Total RNA extraction from cultured cells
Total RNA was extracted using TRIzol reagent followed by further purification with a PureLink RNA Mini Kit in accordance with the manufacturer's instructions (Thermo Fisher Scientific).
Microarray analysis
Transcriptome-wide splicing analysis was carried out using purified total RNAs and a GeneChip â Human Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA, USA) at TaKaRa (Shiga, Japan). After the signals had been normalized using AFFYMETRIX GENECHIP COMMAND CONSOLE Software 4.0 and EXPRESSION CONSOLE Software 1.4.1, alternative splicing and differential expression at the gene level were analyzed using AFFYMETRIX TRANSCRIPTOME ANALYSIS CONSOLE Software 3.0.
Analysis of the splicing pattern
Purified total RNAs were reverse-transcribed into cDNAs using random hexamer primers and Superscript III in accordance with the manufacturer's instructions. The resultant cDNAs were amplified by PCR with Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific) and the following primers:
0 ) and ELN_DW (5 0 -ctgggaaaatgggagacaa tccg-3 0 ). PCR products were separated on Novex 10% TBE gels (Thermo Fisher Scientific), and the intensity of each band was quantified using IMAGEJ software (http://rsb.info.nih.gov/ij/) after staining with SYBR Safe DNA Gel Stain Dye.
Synthesis of expression constructs for Matrin3 and its deletion mutants
A full-length expression construct for human Matrin3 tagged with a HaloTag at the N-terminus was obtained from Promega (Madison, WI, USA) and the coding sequence was transferred to the expression vector p3xFLAG-CMV10 (Sigma). The resultant construct was termed p3xFLAG-CMV10-Matrin3 WT. The expression construct for the mutant in which both RRMs were deleted, which was termed p3xFLAG-CMV10-Matrin3 DRRM1 + 2, was generated by a two-step PCR extension method as described previously (Kawahara & Mieda-Sato 2012) . In brief, two Matrin3 fragments were amplified with the primers hMatrin3_FW1_del (5 0 -ttgagttatggtaggatggcag-3 0 ) and hMatrin3_dRRM1_RRM2_DW1 (5 0 -tcctcagaaccagttttttatacatgtgtc-3 0 ) and with the primers pCMV10_DW1 (5 0 -tattaggacaaggctggtgggc-3 0 ) and hMatrin3_dRRM1_RRM2_FW1 (5 0 -cctgcaaggacctagacacatgtataaaaa-3 0 ), respectively. After gel purification, a second round of amplification was then carried out with the primers hMatrin3_FW1_del and pCMV10_DW1 using a mixture of the two fragments as the template. The resultant PCR products were digested with AvrII and BamHI-HF (NEB) and then inserted into p3xFLAG-CMV-10-Matrin3 that had been linearized with the same restriction enzymes. Finally, the regions that corresponded to Matrin3 WT and DRRM1 + 2 were amplified by PCR and inserted into the pTNT vector (Promega) after digestion with KpnI and NotI (NEB).
Preparation of Matrin3-and TDP-43-target RNAs
To generate the expression constructs for Matrin3-target RNAs, which were used for reverse EMSA, we amplified two fragments that corresponded to a certain intronic region of FGF14 ( Fig. S2B in Supporting Information) using human genomic DNA (Merck Millipore) as the template with the primers FGF14ab_FW (5 0 -atatgtaatcagacatcaag-3 0 ) and FGF14a_DW (5 0 -catattacatgcagaaagaa-3 0 ) and with the primers FGF14ab_FW and FGF14b_DW (5 0 -acgaaagctgaaaaaagcat-3 0 ), respectively. The PCR products were gel-extracted and inserted into the vector pCR BluntII-TOPO (Thermo Fisher Scientific). The resultant constructs were termed FGF14a and FGF14b. To construct FGF14c (Fig. S2B in Supporting Information), the synthesized complementary oligonucleotides (5 0 -atatgtaatcagacatcaag-3 0 and 5 0 -cttgatgtctgattacatat-3 0 ) were mixed in the annealing buffer (10 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA), incubated at 95°C for 15 min and cooled down gradually. The annealed oligonucleotides were inserted into pCR BluntII-TOPO. After the direction of the insertion had been confirmed by sequencing, the construct was linearized with the restriction enzyme SpeI (NEB) and in vitro transcription was carried out with T7 RNA polymerase using a Riboprobe â In Vitro Transcription System (Promega) at 37°C for 1 h. After treatment with RQ1 RNase-Free DNase (Promega), the resultant RNA fragments were recovered by phenol extraction and 2-propanol precipitation with glycogen. After the concentration had been measured using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific), the final concentration was adjusted to 1-100 ng/lL and the RNAs were stored at À80°C until use. The target RNAs of TDP-43, namely miR-143-3p and UG12, were synthesized by Hokkaido System Science (Sapporo, Japan), as described previously (Kawahara & Mieda-Sato 2012 35 S]-Methionine. Aliquots of the reaction mixtures were loaded onto NuPAGE Novex 4%-12% Bis-Tris gels (Thermo Fisher Scientific), and the gels were exposed overnight to visualize the radiolabeled proteins on a phosphorimager. Then, the reverse EMSA was carried out as described previously (Filion et al. 2006 ) with modifications. In brief, the radiolabeled proteins (3 lL for Matrin3 and 1.5 lL for TDP-43) were incubated at 25°C for 25 min with the indicated amounts of RNA (0.5-50 ng for Matrin3 and 50 ng for TDP-43) in a 20-lL reaction mixture that contained 10 mM Tris-HCl pH 8.0, 25 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 10% glycerol and 0.5 mM DTT. The reaction products were loaded on a 6% DNA retardation gel (Thermo Fisher Scientific) and separated by electrophoresis at 200 V for 2 h or 20 min for Matrin3 and TDP-43, respectively, with cooling. Then, the gels were exposed overnight and visualized using a phosphorimager.
In the competition assay, the indicated amount of nonradiolabeled Matrin3 protein (1.0-5.0 9 the volume of radiolabeled Matrin3 protein) was incubated with 50 ng of FGF14a RNA at 25°C for 10 min before the addition of radiolabeled protein.
Statistical analysis
The statistical analyses of the differences in splicing patterns and expression levels using the microarray data were carried out using one-way ANOVA and Welch's t-test, respectively. All other analyses were carried out using the Mann-Whitney Utest. All values are displayed as the mean AE standard error of the mean (SEM). Statistical significance is displayed as P < 0.05 (*).
Accession numbers
The PAR-CLIP data used in this study are available through the DNA Data Bank of Japan (DDBJ) under accession numbers DRA005124 and DRA005839. Microarray data are available through the Gene Expression Omnibus (GEO) under accession number GEO86967. 
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article: 
